SEARCH:   Advanced

Blood, 1 May 2007, Vol. 109, No. 9, pp. 3658-3666. Prepublished online as a Blood First Edition Paper on January 9, 2007; DOI 10.1182/blood-2006-06-025627. This Article Full Text Full Text (PDF) Supplemental Appendix All Versions of this Article: blood-2006-06-025627v1 109/9/3658    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Cornelissen, J. J. Articles by Lowenberg, B. Search for Related Content PubMed PubMed Citation Articles by Cornelissen, J. J. Articles by Lowenberg, B. Related Collections Transplantation Clinical Trials and Observations Neoplasia Related Articles in Blood Online Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  CLINICAL TRIALS AND OBSERVATIONS Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom? Jan J. Cornelissen1, Wim L. J. van Putten1, Leo F. Verdonck2, Matthias Theobald3, Emanuel Jacky4, Simon M. G. Daenen5, Marinus van Marwijk Kooy6, Pierre Wijermans7, Harry Schouten8, Peter C. Huijgens9, Hans van der Lelie10, Martin Fey11, Augustin Ferrant12, Johan Maertens13, Alois Gratwohl14, and Bob Lowenberg1 1 Erasmus University Medical Center, Rotterdam, The Netherlands; 2 University Medical Center Utrecht, Utrecht, The Netherlands; 3 Johannes Gutenberg University, Mainz, Germany; 4 University Hospital Zurich, Zurich, Switzerland; 5 University Medical Center Groningen, Groningen, The Netherlands; 6 Isala Klinieken, Zwolle, The Netherlands; 7 Haga Hospital, Den Haag, The Netherlands; 8 University Hospital Maastricht, Maastricht, The Netherlands; 9 Free University Medical Center, Amsterdam, The Netherlands; 10 Amsterdam Medical Center, Amsterdam, The Netherlands; 11 University Hospital, Bern, Switzerland; 12 Cliniques Universitaires Saint-Luc, Brussels, Belgium; 13 University Hospital Gasthuisberg, Leuven, Belgium; 14 Kantonsspital, Basel, Switzerland The Dutch-Belgian Hemato-Oncology Cooperative Group and the Swiss Group for Clinical Cancer Research (HOVON-SAKK) collaborative study group evaluated outcome of patients (pts) with acute myeloid leukemia (AML) in first remission (CR1) entered in 3 consecutive studies according to a donor versus no-donor comparison. Between 1987 and 2004, 2287 pts were entered in these studies of whom 1032 pts (45%) without FAB M3 or t(15;17) were in CR1 after 2 cycles of chemotherapy, received consolidation treatment, and were younger than 55 years of age and therefore eligible for allogeneic hematopoietic stem cell transplantation (allo-SCT). An HLA-identical sibling donor was available for 326 pts (32%), whereas 599 pts (58%) lacked such a donor, and information was not available in 107 pts. Compliance with allo-SCT was 82% (268 of 326). Cumulative incidences of relapse were, respectively, 32% versus 59% for pts with versus those without a donor (P < .001). Despite more treatment-related mortality (TRM) in the donor group (21% versus 4%, P < .001), disease-free survival (DFS) appeared significantly better in the donor group (48% ± 3% versus 37% ± 2% in the no-donor group, P < .001). Following risk-group analysis, DFS was significantly better for pts with a donor and an intermediate- (P = .01) or poor-risk profile (P = .003) and also better in pts younger than 40 years of age (P < .001). We evaluated our results and those of the previous MRC, BGMT, and EORTC studies in a meta-analysis, which revealed a significant benefit of 12% in overall survival (OS) by donor availability for all patients with AML in CR1 without a favorable cytogenetic profile. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? Related Articles in Blood Online: HLA-identical sibling stem-cell transplantation in first-remission AML Sikander Ailawadhi and Swaminathan Padmanabhan Blood 2007 110: 4619. [Full Text] [PDF] Response: Allogeneic hematopoetic stem-cell transplantation in acute myeloid leukemia Jan J. Cornelissen, Wim van Putten, and Bob Löwenberg Blood 2007 110: 4619-4620. [Full Text] [PDF] This article has been cited by other articles: W. Blum Post-remission therapy in acute myeloid leukemia: what should I do now? Haematologica, June 1, 2008; 93(6): 801 - 805. [Full Text] [PDF] R. F. Schlenk, K. Dohner, J. Krauter, S. Frohling, A. Corbacioglu, L. Bullinger, M. Habdank, D. Spath, M. Morgan, A. Benner, et al. Mutations and Treatment Outcome in Cytogenetically Normal Acute Myeloid Leukemia N. Engl. J. Med., May 1, 2008; 358(18): 1909 - 1918. [Abstract] [Full Text] [PDF] B. Lowenberg Diagnosis and Prognosis in Acute Myeloid Leukemia -- The Art of Distinction N. Engl. J. Med., May 1, 2008; 358(18): 1960 - 1962. [Full Text] [PDF] S. Lugthart, E. van Drunen, Y. van Norden, A. van Hoven, C. A. J. Erpelinck, P. J. M. Valk, H. B. Beverloo, B. Lowenberg, and R. Delwel High EVI1 levels predict adverse outcome in acute myeloid leukemia: prevalence of EVI1 overexpression and chromosome 3q26 abnormalities underestimated Blood, April 15, 2008; 111(8): 4329 - 4337. [Abstract] [Full Text] [PDF] S. Ailawadhi and S. Padmanabhan HLA-identical sibling stem-cell transplantation in first-remission AML Blood, December 15, 2007; 110(13): 4619 - 4619. [Full Text] [PDF] J. J. Cornelissen, W. van Putten, and B. Lowenberg Response: Allogeneic hematopoetic stem-cell transplantation in acute myeloid leukemia Blood, December 15, 2007; 110(13): 4619 - 4620. [Full Text] [PDF]

	Blood Online is supported in part by Genentech BioOncology and Biogen Idec
	Copyright © 2007 by American Society of Hematology         Online ISSN: 1528-0020